Sangamo Therapeutics (SGMO) News Today $1.95 -0.01 (-0.51%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Research Analysts Set Expectations for SGMO FY2024 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Sangamo Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical companyNovember 18 at 1:49 AM | marketbeat.comWhat is HC Wainwright's Estimate for SGMO FY2028 Earnings?November 17, 2024 | americanbankingnews.comHC Wainwright Has Bullish Outlook for SGMO FY2028 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities researchers at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Sangamo Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceNovember 15, 2024 | marketbeat.comWells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)November 15, 2024 | markets.businessinsider.comBarclays Raises Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $9.00Barclays boosted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a research note on Thursday.November 14, 2024 | marketbeat.comSangamo Biosciences: Promising Financial Position and Strategic FDA Alignment Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comQ3 2024 Sangamo Therapeutics Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comRBC Capital Remains a Hold on Sangamo Biosciences (SGMO)November 13, 2024 | markets.businessinsider.comSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSangamo options imply 21.0% move in share price post-earningsNovember 13, 2024 | markets.businessinsider.comSangamo Therapeutics Reports Strong Q3 2024 GrowthNovember 13, 2024 | markets.businessinsider.comSangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comSangamo Therapeutics (SGMO) Set to Announce Earnings on TuesdayNovember 11, 2024 | americanbankingnews.comEquities Analysts Set Expectations for SGMO FY2024 EarningsSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceuticalNovember 7, 2024 | marketbeat.comSangamo options imply 14.5% move in share price post-earningsNovember 6, 2024 | markets.businessinsider.comSangamo price target raised to $10 from $5 at H.C. WainwrightNovember 6, 2024 | markets.businessinsider.comSangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on TuesdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 5, 2024 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Sangamo Therapeutics (NASDAQ:SGMO) StockHC Wainwright upped their price target on Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comSangamo Therapeutics Announces Third Quarter 2024 Conference Call and WebcastNovember 4, 2024 | finance.yahoo.comSangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average - Here's WhySangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comTruist Financial Keeps Their Hold Rating on Sangamo Biosciences (SGMO)October 24, 2024 | markets.businessinsider.comSangamo Biosciences (SGMO) Gets a Buy from TD CowenOctober 24, 2024 | markets.businessinsider.comSangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease DrugOctober 23, 2024 | marketwatch.comWhat's Going On With Sangamo Therapeutics Shares Tuesday?October 23, 2024 | msn.comSangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday.October 22, 2024 | marketbeat.comTraders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 6,620 call options on the company. This represents an increase of approximately 173% compared to the typical daily volume of 2,429 call options.October 22, 2024 | marketbeat.comSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025October 22, 2024 | businesswire.comSangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?October 21, 2024 | seekingalpha.comMiller time: Williamsville football stuns New Berlin before halftime in Sangamo winOctober 12, 2024 | sports.yahoo.comSangamo Therapeutics (NASDAQ:SGMO) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Acquired by Renaissance Technologies LLCRenaissance Technologies LLC increased its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 58.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,126,577 shares of the biopharmaceutical companOctober 5, 2024 | marketbeat.comArmistice Capital LLC Has $5.04 Million Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Armistice Capital LLC decreased its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 17.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,060,000 sharesSeptember 27, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200-Day Moving Average of $0.64September 27, 2024 | marketbeat.com3 Penny Stocks To Buy With Just $750September 24, 2024 | 247wallst.comInvestors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past weekSeptember 21, 2024 | finance.yahoo.comSangamo Prices Direct OfferingSeptember 13, 2024 | msn.comSangamo Therapeutics (NASDAQ:SGMO) Shares Pass Above Two Hundred Day Moving Average of $0.66Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Passes Above 200 Day Moving Average of $0.66September 7, 2024 | marketbeat.comQ4 2025 EPS Estimates for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Cut by AnalystSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Analysts at HC Wainwright decreased their Q4 2025 EPS estimates for Sangamo Therapeutics in a research note issued on Thursday, August 22nd. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earningsAugust 23, 2024 | marketbeat.comStrong Buy Recommendation for Sangamo Biosciences Amidst Strategic Partnerships and Promising Gene Therapy AdvancementsAugust 23, 2024 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a research report on Thursday.August 22, 2024 | marketbeat.comEast Bay biotech company takes aim at one-in-a-million disease. First it needs millions more in cashAugust 19, 2024 | bizjournals.comSangamo Therapeutics, Inc. (0R1D.L)August 18, 2024 | uk.finance.yahoo.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Large Increase in Short InterestSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 19,290,000 shares, an increase of 51.5% from the July 15th total of 12,730,000 shares. Based on an average trading volume of 13,130,000 shares, the days-to-cover ratio is currently 1.5 days.August 14, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price TargetsAugust 9, 2024 | finance.yahoo.comSangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical ProgressAugust 7, 2024 | markets.businessinsider.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | msn.comSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.comWhy Sangamo Therapeutics Stock Is SoaringAugust 7, 2024 | msn.com Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.440.46▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼132▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADAP News CLLS News ATRA News BLUE News DVAX News BCRX News MYGN News NVAX News INVA News OPK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
